Research & Development

Study Finds Muscle Strength Key to a Longer Life
Research & Development Study Finds Muscle Strength Key to a Longer Life

The persistent search for a long and healthy life has often prioritized cardiovascular fitness, yet a groundbreaking study suggests a more fundamental measure of vitality might be found in something as simple as the strength of your grip. This new body of research illuminates a powerful,

Have Scientists Found Leukemia's Off Switch?
Research & Development Have Scientists Found Leukemia's Off Switch?

In the intricate and often relentless world of oncology, a recent discovery has illuminated a previously hidden pathway that governs the very genesis of a deadly blood cancer, suggesting that the key to halting the disease might lie within a mechanism once thought to be part of the problem. This

Could New Antibodies Prevent EBV-Linked Cancers?
Research & Development Could New Antibodies Prevent EBV-Linked Cancers?

As a leading expert in biopharmaceutical research and development, Ivan Kairatov has spent his career at the forefront of medical innovation. Today, he joins us to discuss a significant breakthrough in the fight against the Epstein-Barr virus—a pathogen that infects an estimated 95% of the world's

Cellular Metabolic Engineering – Review
Research & Development Cellular Metabolic Engineering – Review

Reprogramming the fundamental operating system of a cell by rerouting its intricate metabolic pathways is no longer a concept confined to theoretical biology; it is an rapidly advancing field with the power to correct life-threatening genetic defects at their core. Cellular metabolic engineering

Review of Axpaxli AMD Treatment
Research & Development Review of Axpaxli AMD Treatment

In the high-stakes world of pharmaceutical development, a successful Phase 3 trial is typically a cause for celebration, yet Ocular Therapeutix's recent announcement for its wet AMD treatment, Axpaxli, was met with a starkly different reality. The drug achieved its primary endpoint with statistical

First Psychedelic Drug for Depression Nears FDA Approval
Research & Development First Psychedelic Drug for Depression Nears FDA Approval

With a major breakthrough in psychedelic medicine, Compass Pathways' psilocybin-based therapy, COMP360, has delivered compelling Phase 3 results, sending shockwaves through the biopharma world and reigniting hope for patients with treatment-resistant depression. To unpack what this means for

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later